Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 4/20 | 0.32 |
| ▸ | CTSL | P07711 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 3/20 | 0.31 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28405406 | 1.00 | SSTR4 (0.35) | SSTR4RETCTSSCTSLMEN1 | |
| SCHEMBL21112577 | 0.90 | SSTR4 (0.38) | SSTR4RETCTSSCTSLMEN1 | |
| SCHEMBL21112581 | 0.90 | SSTR4 (0.38) | SSTR4RETCTSSCTSLMEN1 | |
| SCHEMBL20908059 | 0.84 | CTSS (0.34) | CTSSCTSLMEN1KMT2AATM | |
| SCHEMBL28407522 | 0.84 | CTSS (0.34) | CTSSCTSLMEN1KMT2AATM | |
| SCHEMBL22579540 | 0.82 | AAK1 (0.40) | CTSSCTSLMEN1KMT2AATM | |
| SCHEMBL29640353 | 0.82 | OPRK1 (0.39) | CTSSMEN1KMT2AOPRK1AAK1 | |
| SCHEMBL28407518 | 0.82 | AAK1 (0.40) | CTSSCTSLMEN1KMT2AATM | |
| SCHEMBL29640239 | 0.82 | TRPV1 (0.38) | CTSSOPRK1F2PRSS1AAK1 | |
| SCHEMBL28407464 | 0.82 | TRPV1 (0.38) | CTSSOPRK1F2PRSS1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352329-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| CN-111212832-A | 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as HIV protease inhibitors | 吉利德科学公司 | 2020-05-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352329-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | SSTR4 4672/4885RET 4730/4885CTSS 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.